Karyopharm Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
KPTI$0.04-27.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except per share amounts)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $72,828 | $52,231 |
| Investments | 60,698 | 139,212 |
| Accounts receivable, net | 31,778 | 26,962 |
| Inventory | 4,672 | 3,043 |
| Prepaid expenses and other current assets | 14,746 | 11,813 |
| Restricted cash | 33 | 660 |
| Total current assets | 184,755 | 233,921 |
| Property and equipment, net | 495 | 606 |
| Operating lease right-of-use assets | 2,586 | 4,276 |
| Restricted cash | 306 | 301 |
| Other assets | 1,334 | 1,334 |
| Total assets | $189,476 | $240,438 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $5,783 | $3,123 |
| Accrued expenses | 50,105 | 61,394 |
| Operating lease liabilities | 3,668 | 3,308 |
| Other current liabilities | 1,937 | 1,654 |
| Total current liabilities | 61,493 | 69,479 |
| Convertible senior notes due 2025 | 24,392 | 170,919 |
| Convertible senior notes due 2029 | 72,091 | — |
| Senior secured term loan | 94,109 | — |
| Deferred royalty obligation | 73,499 | 132,479 |
| Common stock warrants | 17,355 | — |
| Operating lease liabilities, net of current portion | — | 2,789 |
| Other liabilities | 6,184 | 978 |
| Total liabilities | 349,123 | 376,644 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; 5,000 shares authorized; none issued and outstanding | — | — |
| Common stock, $0.0001 par value; 400,000 shares authorized; 125,303 and 114,915 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 13 | 12 |
| Additional paid-in capital | 1,373,242 | 1,350,981 |
| Accumulated other comprehensive loss | (222) | (161) |
| Accumulated deficit | (1,532,680) | (1,487,038) |
| Total stockholders’ deficit | (159,647) | (136,206) |
| Total liabilities and stockholders’ deficit | $189,476 | $240,438 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.